Compare Airbnb, Inc. (ABNB) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Airbnb, Inc. vs BridgeBio Pharma Inc — how do they compare? Airbnb, Inc. trades at $184.69 (market cap $110.60B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: Airbnb, Inc. is far larger — about 6.7× BridgeBio Pharma Inc's market cap, and Airbnb, Inc. is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| ABNB | BBIO | |
|---|---|---|
Market Cap | $110.60B | $16.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.98 | $90.17 |
52-Week Low | $111.54 | $47.29 |
Enterprise Value | $101.02B | $18.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Airbnb (ABNB) is trading at $178.07, up 17.43% with strong momentum after Q2 2026 earnings beat expectations. The stock is approaching four-year highs with bullish technical indicators and positive analyst sentiment. Revenue growth accelerated to $12.24B in 2025 with robust 82.9% gross margins, though recent quarters showed mixed earnings performance with two misses and one beat.
Outlook remains positive with AI-driven growth initiatives and expanding service offerings, but elevated valuation multiples (P/E 40.66) and competitive pressures present risks. Analyst consensus leans bullish with 46.7% buy ratings and $173.26 price target, though current price exceeds consensus target by 2.8%.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Airbnb, Inc.
Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.
Read more on ABNB →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
